Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors

TCD Pharma has developed TCD-717, a novel drug that is a specific inhibitor of the enzyme choline kinase alpha (ChoKα), involved in the synthesis of phosphatidylcholine, which constitutes the major phospholipid in eukaryotic cell membranes and has been described as a potent oncogen when overexpressed in human cells. TCD-717 will be evaluated in this Phase I, open-label, single arm study to be performed at multiple centers. TCD-717 will be administered as a 4 hour infusion on two separate days per 7-day period per 28-day cycle (8 administrations per cycle). Eligible patients must have confirmed, metastatic or recurrent/refractory solid tumors.

Inclusion criteria

• Patients must have histologically-confirmed solid tumors, metastatic or recurrent and refractory after standard therapy for the disease or for which conventional therapy is not reliably effective or no effective therapy is available.
• Where possible, it is recommended that a paraffin block of tumor tissue or slides containing sections of tumor tissue be available (a sample should be collected and stored appropriately for the potential evaluation of choline kinase alpha expression in tumor tissue at the end of the study).
• Patients must be ≥ 18 years of age.
• Patients must have an ECOG Performance Status of 0, 1 or 2 and an estimated life expectancy of ≥ 12 weeks.
• Patients must have adequate clinical laboratory values (i.e., absolute neutrophil count ≥1.5x10^9/L, platelets ≥100x10^9/L, plasma creatinine <= 1.5 x upper limit of normal (ULN) for the institution or a calculated creatinine clearance (using Cockroft and Gault formula) of ≥ 60 mL/min/1.73 m^2; bilirubin < 1.5 x ULN, alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN or ≤ 5 x ULN with liver involvement.
• Patients may have either measurable or non-measurable disease as defined by RECIST.
• Patients must give signed informed consent prior to the start of any study specific procedures.
• Female patients with reproductive potential must have a negative serum or urine pregnancy test.
• Patients with reproductive potential and their partners must be using at least one form of contraception as approved by the Investigator prior to study entry.
• Patients with central nervous system metastases may be included if they are stable without administration of steroids. Patients with unstable metastatic CNS disease are excluded.

Exclusion criteria

• Patients will be excluded if they have received previous anti-cancer chemotherapy, immunotherapy, vaccines, monoclonal antibodies, anti-angiogenic therapy, radiotherapy or any other investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entry. Patients receiving concurrent anticancer therapy or intending to receive this at any time during the study will be excluded.
• Patients who have received extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation at any time prior to the study.
• Patients with any concomitant condition that could compromise the objectives of this study and the patient's compliance.
• Patients with significant cardiac disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions, history of myocardial infarction within six months of study entry, uncontrolled dysrhythmias or poorly controlled angina, uncontrolled hypertension or elevated heart rate.
• Patients with a history of serious ventricular arrhythmia (VT or VF), QTc >=450 msec for men and 470 msec for women (as indicated in the ECG taken in the pre-treatment evaluation), or left ventricular ejection fraction (LVEF)<=50% by MUGA or Echocardiogram performed at the pre-treatment evaluation.
• Pregnant or lactating females.
• Patients with clinically evident HIV, HBV or HCV infection.
• Patients with a hematologic malignancy.
• Patients with a documented or known bleeding disorder or who require anticoagulation treatment that increases international normalized ratio (INR) or activated partial thromboplastin time (aPTT) above the institutional upper limit of normal.
• Patients with clinically significant retinal abnormalities as per the medical history or ophthalmologic findings in the pre-treatment evaluation (e.g., retinitis pigmentosa or macular degeneration).